No holiday for biotech IPOs as Rallybio and Sophia Genetics submit their Nasdaq pitches
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
There’s no stopping the hot IPO market despite the long holiday weekend, as another two biotechs prepared their Nasdaq pitches late last Friday.
Martin Mackay’s Rallybio and the Swiss-based Sophia Genetics each penciled in $100 million raises in their S-1 and F-1 filings, respectively, becoming the latest biotechs to join the IPO craze that remains on pace to top last year’s records. Rallybio and Sophia capped off a week that saw several new filings, including Jennifer Doudna’s Caribou Biosciences, Paul Peter Tak’s Candel Therapeutics, Absci and Erasca.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.